The Orlando ASH Report
So where were you last week? You missed ASH and the MPN gene editing seminar. And you weren’t at the MPN Heroes’ Ball. Don’t worry. We can get you up to speed without you going to all the expense and bother of travel and airport security. Read on.
Last week’s annual meeting of the American Society of Hematology kicked off with a perfect smorgasbord of MPN events: The preliminary ASH morning meetings, the CREATE lunch seminar exploring gene therapy for MPNs, and the MPN Heroes dinner event in the evening.
Most of us will never attend an ASH annual meeting. On a practical level, for MPN patients and their caregivers, this mammoth yearend event produces reports of work in progress and breakthrough scientific findings to help us and our hematologists calibrate our therapeutic options.
Sorting through the immense detail and conflicting claims remains a task for others. Having attended these MPN events and met with many investigators and researchers we can only offer two items of any likely value to our MPN community: Our sense of the treatment landscape – what drugs and treatment options are at hand and what’s just over the horizon — and a candid look at the processes of these three meetings and what they say about our MPN community and our prospects for management and cure.
You can enter the conversation and further our understanding by contributing your own experiences in the COMMENTS space after each section.
Straight scoop on ASH, MPN drugs, clinical trials and credible scuttlebutt.
Drugs: Imetelstat, PRM-151, Pacritinib, Interferon + rux… Clinical trials: Two clinical trials to keep on your radar, one you never heard of. Scuttlebutt: Tefferi and Mascarenhas score… (It’s all in The Orlando ASH report)
The CREATE Seminar
When it comes to MPN gene therapy there’s still a lot of stuff to sort out. With all the upbeat news — a gene edited leukemia cure, surging CAR-T and immunotherapy and gene therapy trials — the Seminar cites promise, cautions patience. (MPN CRISPR What are we waiting for?)
MPN Heroes –Evolution of an academy award.
Who won the crystal JAKkie this year and is it all worthwhile? (Photos/story Confessions of an MPN Hero Whore)
In the current MPN Quarterly Journal issue: The hidden face of Janus … CHZ868, an experimental Type II JAK2 inhibitor targets inactive state of JAK2, rolls back MPN symptoms, reduces allele burden, and overcomes ruxolitinib resistance. Plus: The Power of the pseudokinase: Molecular modeling of the autoinhibitory action between the kinase and pseudokinase uncovers hidden pathogenic mechanism. Coming next month: “Looking forward: Novel therapeutic approaches in chronic and advanced phases of myelofibrosis,” by John Mascarenhas.
Tell your story, express yourself, share your experience in your MPN magazine. You can add your comments to MPNforum articles, list your Blog, or write an article. (We’ll even help you get started.)…Letter to the Editor
© MPNforum, LLC , MPNforum.com, and the MPNforum Quarterly Journal 2015. MPNforum is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. Unauthorized use and/or duplication of this material without express and written permission is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to MPNforum.com with appropriate and specific direction to the original content.
.Donations are welcome but not tax-deductible